Gluten-Free Basics ‘Now a Luxury’ as Price of a Small Branded Loaf Nears £4

Why It Matters

Rising costs threaten the accessibility of a medically necessary diet, potentially worsening health outcomes for millions of coeliacs and reshaping retailer strategies around specialty foods.

Key Takeaways

• Gluten‑free bread prices rose 6% YoY, reaching £3.90
• Weekly gluten‑free shop can cost 35% more than regular
• Retailers cite specialist facilities and testing as cost drivers
• Gluten‑free product launches fell from 19% to 12% (2019‑2025)
• Coeliac UK finds 8 in 10 struggle affording free‑from staples

Pulse Analysis

The UK’s free‑from aisle is feeling the pressure of a perfect storm of macro‑economic forces. After the 2022 Ukraine invasion, food inflation slowed but is now accelerating again as the Iran war pushes energy and commodity costs upward. Gluten‑free manufacturers, already burdened by dedicated production lines and rigorous segregation protocols, are seeing input costs climb 10% or more. This translates into higher shelf prices for breads, flours and cereals, with a typical loaf now costing £4 (about $5.10) – a stark contrast to the sub‑£1 price of conventional white bread.

For consumers, the impact is immediate and painful. Coeliac disease requires strict avoidance of gluten, making these products a non‑negotiable part of the diet. Research from Coeliac UK shows a weekly gluten‑free shop can be up to 35% more expensive than a standard grocery run, and eight in ten sufferers report difficulty affording basics. The price gap forces some families to compromise, buying cheaper “may contain gluten” items or reducing consumption altogether, which can jeopardise health. The loss of low‑cost options, such as Aldi’s trial of free‑from items, further narrows access for price‑sensitive shoppers.

Retailers and manufacturers are responding cautiously. While supermarkets like Tesco claim to maintain product counts, the share of new gluten‑free launches has dropped from 19% in 2019 to 12% in 2025, reflecting tighter margins and higher development costs. Companies such as Doves Farm emphasize price‑keeping efforts, yet ultimate shelf pricing remains retailer‑driven. Industry analysts warn that unless supply‑chain efficiencies improve or subsidies are introduced, gluten‑free foods will continue to sit at the premium end of the market, reinforcing a divide between those who can afford medically essential products and those who cannot.